How Labcorp Holdings Inc. Makes Money

Labcorp generates revenue through two distinct business segments. Diagnostics Laboratories, contributing approximately 79.2% of FY2024 revenue at $10.31 billion, provides routine and specialty diagnostic testing services to patients, physicians, hospitals, and health systems. Revenue flows from specimen collection (through patient service centers, phlebotomists, and hospital partnerships), laboratory processing (at primary laboratories and specialized facilities), and result reporting. The segment includes routine testing such as blood chemistry, hematology, urinalysis, and microbiology; specialty testing including oncology, women's health, neurology, autoimmune diseases, and genetic/genomic testing; and pathology services. Labcorp's network includes approximately 2,000 patient service centers, a national courier infrastructure, and relationships with thousands of hospitals and physician practices. The economics of diagnostic testing depend on test volume, payer mix, and test complexity. Routine tests have lower margins but higher volume, while specialty tests command premium pricing but require specialized equipment and expertise. In 2024, Labcorp launched more than 130 innovative new tests, expanding its menu in high-growth therapeutic areas. The segment's adjusted operating margin was approximately 14.9% in 2024, reflecting the benefits of scale, automation, and operational efficiency initiatives. Biopharma Laboratory Services, contributing approximately 20.8% of revenue at $2.70 billion, provides laboratory support to pharmaceutical and biotechnology companies engaged in drug development. Services include central laboratory services for clinical trials, bioanalytical testing, companion diagnostic development, and genomic testing. Revenue is generated through long-term contracts with drug developers, with backlog providing visibility into future performance. The segment's $7.9 billion backlog at the end of 2024 included approximately $2.46 billion expected to convert to revenue in the next twelve months. Net orders and net book-to-bill during the trailing twelve months were $2.83 billion and 1.00, respectively. The segment's adjusted operating margin was approximately 9.8% in 2024, lower than Diagnostics due to higher personnel costs and the capital-intensive nature of clinical trial support infrastructure. Labcorp's payer mix in Diagnostics is weighted toward commercial insurance and Medicare, with Medicaid and self-pay representing smaller portions. Commercial rates are negotiated annually with insurers, while Medicare rates are set by federal regulation. The company faces ongoing pricing pressure from Medicare reimbursement cuts, including the Protecting Access to Medicare Act (PAMA) which reduced clinical laboratory fee schedule rates. Labcorp's cost structure includes laboratory personnel, reagents and supplies, equipment depreciation, logistics, and information technology. The company has implemented automation and artificial intelligence to reduce manual processing costs and improve turnaround times. The LaunchPad business process improvement initiative targets $100 million+ in annual cost savings through operational optimization.

Labcorp's growth strategy under CEO Adam Schechter centers on four pillars: specialty testing expansion, health system partnerships, operational excellence, and strategic acquisitions. The first pillar concentrates resources on high-growth testing categories including oncology (companion diagnostics, liquid biopsy, tumor profiling), women's health (prenatal screening, reproductive genetics), neurology (Alzheimer's biomarkers, autoimmune neurology), and autoimmune diseases. In 2025, Labcorp launched more than 130 innovative new tests in these areas. The second pillar, health system partnerships, involves lab management agreements, outreach acquisitions, and regional laboratory partnerships that convert competitors into customers. The 13 transactions signed or closed in 2025 demonstrate execution momentum. The third pillar, operational excellence, is driven by the LaunchPad initiative targeting $100 million+ in annual cost savings through process automation, supply chain optimization, and organizational efficiency. In 2024, LaunchPad savings contributed to margin improvement despite PAMA reimbursement headwinds. The fourth pillar, strategic acquisitions, focuses on tuck-in deals that expand specialty capabilities or geographic presence. The 2024 acquisitions of Invitae select assets (oncology and rare disease genetics) and BioReference Health's diagnostic business (clinical diagnostics and reproductive health) exemplify this approach. The company has also announced a strategic investment to build a modern 500,000 square foot Central Laboratory facility to address growth demand. Capital allocation balances growth investments with shareholder returns, with 2025 guidance including continued share repurchases and dividend maintenance.